Functional Characterization of Human CYP2C9 Allelic Variants in COS-7 Cells

被引:10
|
作者
Du, Huihui [1 ,2 ]
Wei, Zhiyun [1 ,2 ]
Yan, Yucai [1 ,2 ]
Xiong, Yuyu [1 ,2 ]
Zhang, Xiaoqing [3 ]
Shen, Lu [1 ,2 ]
Ruan, Yunfeng [1 ,2 ]
Wu, Xi [1 ,2 ]
Xu, Qingqing [1 ,2 ]
He, Lin [1 ,2 ,4 ]
Qin, Shengying [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, BioX Inst, Shanghai 200030, Peoples R China
[2] Shanghai Genome Pilot Inst Genom & Human Hlth, Shanghai, Peoples R China
[3] Shanghai Pulm Hosp, Dept Pharm, Shanghai, Peoples R China
[4] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China
来源
FRONTIERS IN PHARMACOLOGY | 2016年 / 7卷
关键词
cytochrome P450; genetic polymorphisms; pharmacokinetics; in vitro models; HPLC (high-performance/pressure liquid chromatography); S-warfarin; Chinese Han; HUMAN LIVER-MICROSOMES; IN-VITRO ASSESSMENT; AMINO-ACID; CYTOCHROME-P450; WARFARIN; POPULATION; METABOLISM; POLYMORPHISM; PHENYTOIN;
D O I
10.3389/fphar.2016.00098
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Variability in activity of CYP2C9, which is involved in the metabolism of approximately 15% of current therapeutic drugs, is an important contributor to interindividual differences in drug response. To evaluate the functional alternations of CYP2C9*2, CYP2C9*3, CYP2C9*8, CYP2C9*11 and CYP2C9*31, identified in our previous study in Chinese Han population, allelic variants as well as the wild-type CYP2C9 were transiently expressed in COS-7 cells. Kinetic parameters (Km. Vmax, and Clint) for S-warfarin 7-hydroxylation by these recombinant CYP2C9s were determined. Relative to CYP2C9.1, recombinant CYP2C9.3 and CYP2C9.11 exhibited significantly higher Km values, and all allelic variants showed significantly decreased Vmax and Clint values. Among all allelic variants, catalytic activity of CYP2C9.3 and CYP2C9.11 reduced the most (8.2% and 9.8% of Clint ratio, respectively; P < 0.001). These findings should be useful for predicting the phenotype profiles of CYP2C9 in Chinese Han population, comparing the functional results of these alleles accurately, and finally optimizing pharmacotherapy of drug treatment.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Expression and functional characterization of a pHis-tagged human bradykinin B2 receptor in COS-7 cells
    Müller, S
    Adomeit, A
    Kaufmann, R
    Appelhans, H
    Passow, H
    Reissmann, S
    Liebmann, C
    BIOLOGICAL CHEMISTRY, 2000, 381 (04) : 343 - 347
  • [42] Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient
    Dai, Da-Peng
    Li, Chuan-Bao
    Wang, Shuang-Hu
    Cai, Jie
    Geng, Pei-Wu
    Zhou, Yun-Fang
    Hu, Guo-Xin
    Cai, Jian-Ping
    PHARMACOGENOMICS, 2015, 16 (13) : 1475 - 1486
  • [43] Roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone
    Kaori Matsumoto
    Tetsuya Hasegawa
    Kosuke Ohara
    Chihiro Takei
    Masayuki Akimoto
    Journal of Pharmaceutical Investigation, 2020, 50 : 71 - 79
  • [44] Roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone
    Matsumoto, Kaori
    Hasegawa, Tetsuya
    Ohara, Kosuke
    Takei, Chihiro
    Akimoto, Masayuki
    JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2020, 50 (01) : 71 - 79
  • [45] The Expression of Genetic Variants of Cytochrome CYP2C9*2 and CYP2C9*3 and their Association with Increased Risk of Lung Cancer
    Katalinic, Darko
    Aleric, Ivan
    Vcev, Aleksandar
    Bildat, Stephan
    Soerensen, Lilly
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 134 - 134
  • [46] CYP2C9 polymorphisms in human tumors
    Knüpfer, H
    Stanitz, D
    Preiss, R
    ANTICANCER RESEARCH, 2006, 26 (1A) : 299 - 305
  • [47] In vitro expression of CYP21-mutants in COS-7 cells
    Ohlsson, G
    Lajic, S
    Schwartz, M
    EUROPEAN JOURNAL OF HUMAN GENETICS, 1998, 6 : 145 - 145
  • [48] Functional characterization of 20 allelic variants of CYP1A2
    Ito, Miyabi
    Katono, Yuki
    Oda, Akifumi
    Hirasawa, Noriyasu
    Hiratsuka, Masahiro
    DRUG METABOLISM AND PHARMACOKINETICS, 2015, 30 (03) : 247 - 252
  • [49] VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients
    Markatos, Christos N.
    Grouzi, Elissavet
    Politou, Marianna
    Gialeraki, Argyri
    Merkouri, Efrosyni
    Panagou, Ioannis
    Spiliotopoulou, Ioanna
    Travlou, Anthi
    PHARMACOGENOMICS, 2008, 9 (11) : 1631 - 1638
  • [50] Pharmacogenomic Next-Generation DNA Sequencing: Identification and Functional Characterization of Variants of Unknown Significance in CYP2C9 and CYP2C19
    Devarajan, Sandhya
    Moon, Irene
    Black, John Logan
    Bielinski, Suzette
    Larson, Nicholas
    Neavin, Drew
    Wang, Liewei
    Weinshilboum, Richard
    Reid, Joel
    FASEB JOURNAL, 2017, 31